{"name":"Kaken Pharmaceutical","slug":"kaken-pharmaceutical","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ecclock","genericName":"SOFPIRONIUM BROMIDE","slug":"sofpironium-bromide","indication":"Hyperhidrosis","status":"marketed"}]}],"pipeline":[{"name":"Ecclock","genericName":"SOFPIRONIUM BROMIDE","slug":"sofpironium-bromide","phase":"marketed","mechanism":"Ecclock works by blocking the muscarinic acetylcholine receptor M3, which reduces sweat gland activity.","indications":["Hyperhidrosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-08","type":"earnings","source":"simplywall.st","summary":"Kaken Pharmaceutical (TSE:4521) Quarterly Profit Contrasts With Loss-Making Trailing Year Narrative - simplywall.st","headline":"Kaken Pharmaceutical (TSE:4521) Quarterly Profit Contrasts With Loss-Making Trailing Year Narrative","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxNa2VvQVVjdEVGaFR6UEE3T0MtSzMxYlc4dGhFWU85Z1NHU1N5eEdRSGRnUjBKMmhfVFd5NlQ4NGhCNlBjV0p5TDMwMWc0MklhaGhqYXlRZVRJS3BPTWpRQ1QyZ01aZ2QxM0xBTVgyMUNteFFIYmtrR2stangzenJYeXdHbFY1ZmQzNkxFTHh1SVQ4RUxidVM1ZFlSaHhTLVVvc2NOczl5M1AyaUpiTmRMX1VpclpYdGxtX0J1U3BzS25lQktySHRVcXJGcjBFeFlTcGpyclBSMTRiaHQ3WGZNeEVqSlFTNUsycFhpc0dhR0MzdDdMWVRkS1ZTQ3VtRWR5NmhnSWp2Y2c4UkpETmEyUUc5b0Z4ZnpXUzNYcGdfdC1XYzZVcFE?oc=5","date":"2025-12-22","type":"regulatory","source":"Business Wire","summary":"KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire","headline":"KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxOaGx6SFhsVlBYMUxFR0I5WlExZDNDYk5LWU15QzlLMDh2bkw3b0UwM01xQ1lrOUNxd1U0Q1NxTVNsc1hkelFzRjEzY2ZoZjF6dF9xbUliTEpuVGRRS2daRHpiMGhlbVlQWnhUSzNabUxLM2NyU0dxa2lWanBMMWhjMWtQMkNMTnFCN3NDdDNPdkRvWjdRMS1wcV9UOHozU3huUjdJeXlNTlJLRDV5LS0yV0NyeUhMNXltWWZCVHMyaDg4SWViTFlXeEhDMi1GM3FjeUxIbmpBT3ZVN2l4bzJ6TnhfVTRhU1RxeDRQNTZuMW5TSDZPTWtGM2lnOGpZZVdUTmpoQjFMOVVseEVDQWhfVHNvOEZFQ1ZMVWFV?oc=5","date":"2025-08-06","type":"pipeline","source":"Business Wire","summary":"Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan - Business Wire","headline":"Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart fo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPSmVTRjRVTEU0Z3ZaeUgyaWxrVURZWG92dU9CNEhMMGF1VFFXUlMyWXpUbVBXUE05NFBwRjFRRG5mYnB4RktKbTNRQUtjb0I5Vk82dUd6blEzUDZKRXdjRU96cUFzVjAtZXVWX095XzAzWTVUQWlPcW9uVUw0OVZUMkF4V0hsTjVCXzY4aEpoX05BTG5VakNCR3VOZk5OdG9uSjlpUkN2WnpIMFJfRlpzaVRVb0dCZTll?oc=5","date":"2025-08-06","type":"deal","source":"Fierce Biotech","summary":"Kaken strengthens late-stage HAE portfolio with $32M deal for rights to Astria's navenibart in Japan - Fierce Biotech","headline":"Kaken strengthens late-stage HAE portfolio with $32M deal for rights to Astria's navenibart in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9iTDhhTEJTRm1YZk9jX05fOHhLSDExdXFYbFV0QzVCazJOcUVIek1TTk9ydzJnbTBiekNUTGM4QkZHamxLRmlIaGJrR3pHdkdOYjdtRDRRNTh2aXNmRUduMEZ1MGNXS2lMR0ZnT2RVZmpqWXkx?oc=5","date":"2025-04-09","type":"deal","source":"The Pharma Letter","summary":"KalVista licensing deal with Kaken - The Pharma Letter","headline":"KalVista licensing deal with Kaken","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE1sVmZFS2hUdTNBVUNkQzQ4LVJsbF9LWWxpZnJ1Z0JwWTdTWVRWc19ZRFltRGdoTFBJR2pfeC1tNXlEN0hHVk1zb1QyNUFHOXhDNFgwdmtMZHh0Tl9VWjZFX05ldV9ybFktVGZQRU84LXU1ejVsZ0JtRUhzR1U?oc=5","date":"2025-04-08","type":"pipeline","source":"Pharmaceutical Technology","summary":"KalVista licences HAE therapy commercialisation rights to Kaken - Pharmaceutical Technology","headline":"KalVista licences HAE therapy commercialisation rights to Kaken","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNVDcwemdWajJsa19jaEg2RUMzMUFobUZ4VGxYZmF5aVMzam5Rd2N1MWNWNjJKWV8wUy1kSEJfUTRoa3JpSGNGa1ZNYzdoTGtBZ3JweEd3VXFfeFQxMjl3UUdlZGpYVnRMcmJpcXU3b0pBR2txWF9CWnlvdDFRNUxTVEZSUUNManI1anBmT0d5S1NaLWM1bkF4cDJDekZRWGZ5dmpqTFdLU3hDMlE1MjBIS3VUckhFWEZDZ0p6WlFiMXFpVE96WnJOTm5XUHFidENhLVA3N0VEQWxQZXdqN2U3cGx2Y29xeWV1dFdQQ2RBNEF3SE5peWVhYUpqSUZYXzE1X3Vubnc4WWZjWVBvU0pUNElGZzRYS2Za?oc=5","date":"2025-03-26","type":"pipeline","source":"PR Newswire","summary":"Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals - PR Newswire","headline":"Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Ph","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPYWR4cHRscHdaYUJEMUNra2lab3YxZmpMbXVPR25HcXhiSlA4V3RpS0pYZVpvNXZhUTFPTHBVZVJkOVRMc3ZPUXY0aXF3a0o3VTdIWWhOaERlampHbjJLRERKSkFWc2xxWVNRamFJRkUwSThDY2ZuSlY2QjI5RnlXanZUOHVHLVF3dzM0Z2NiRG1MTEZJa0Q2b2tHOGttV3hFVXdPRlRoU1NIekVtMm0wN2JVYWVDRC1L?oc=5","date":"2025-03-26","type":"pipeline","source":"citybiz","summary":"Whitehawk Therapeutics Closes Sale of Aadi Subsidiary to Kaken Pharmaceuticals - citybiz","headline":"Whitehawk Therapeutics Closes Sale of Aadi Subsidiary to Kaken Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBIdHJfS3BsWExSWnBUb1FkY21vSXZmcTRxWGJTMU5SdGNLbzEtdm1OOGo1dGVlaEJVcDJILVpfV2t2MDN0RjNlck9yRUFzSVNteU8w?oc=5","date":"2025-03-26","type":"pipeline","source":"FirstWord Pharma","summary":"Kaken locks in Japan rights for Alumis' dermatology asset - FirstWord Pharma","headline":"Kaken locks in Japan rights for Alumis' dermatology asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxPczBfaVpEa0Q5cWxMWFB5ampONGE5RUR0N21QWHNTWm9HejlDdjVWYjBuS3ZoemZSRlFRXzF2Tkk1WF9LUllFSE9RVUVnbFNhQnJhX05ET19LdFh1ZEhBLWNEb3B0MmloUDE0MVFWVkhCSlJyd3FfR0oyV1UxTE9fcm4yNVhoV3J5RHZpLU5wcnhKQ1k3ZElGdVBQbENVMG84Q2pCS2tNZm1PN0otMXRqWWhsZW42ajZpbG0tRmoweXRqN19tNnB6bFhiTmthbS1LTjJaOU5IVXNmcGNxOFNsbFFQU250QUN2bEtfcnQwNGhTV0FpMkY5S1BMTFloSjdscFY4b0JxelNKZ1FIZzVtWkYzQmk?oc=5","date":"2025-03-25","type":"deal","source":"GlobeNewswire","summary":"Alumis and Kaken Pharmaceutical Announce Collaboration and - GlobeNewswire","headline":"Alumis and Kaken Pharmaceutical Announce Collaboration and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPd0Zzd3VGWFFBc1V5V3k3eHhreTg0M2RocG53M2RYZGljUHNnMFVkLTJiOXdid2k4UXZLZ0d1QWNYQVctS1lPUDF0eDhWazFKOEJuUnFhOERfa2w3VkhBZHJHMmpaUE9ZYzktOElZZFp6WlN2bFZxZUZmbkttUndRMl9NOUlkaDJaSXZRczNfZzR1bDZMdnJLUDI1b0V1dno2TUd6bS12UEcwTTJwWXJN?oc=5","date":"2025-01-06","type":"deal","source":"PMLiVE","summary":"J&J expands atopic dermatitis pipeline with Kaken Pharmaceutical licensing deal - PMLiVE","headline":"J&J expands atopic dermatitis pipeline with Kaken Pharmaceutical licensing deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOc0lpTWpZYjRJZlZNcXpMUU5NdDJMTHRPd0hjRFAzMUJzd3c0RFlvNHJIMGEwSkFMWGRManV4UW9SbUVuenFpanJIdnVrdnBsclFTM1MyNS11Zkp0YU5oTks3S3pYQ1ZkbDNSWWxLWXUtN25kWU92NGZCejM2RW9LRDU5S2VLVl9YNlM5eW5OV2stR3RwOU12VFVGN2JKeDBfRU1LYkh1Zlk5aUpodXlKU29MNTZBNHhvQ0ZtUUVMY1lMeVZMUDBIUkVQLUhfSnZGY0ZuMDA4RDBNaXczRkE?oc=5","date":"2025-01-03","type":"pipeline","source":"Pharmaceutical Executive","summary":"Johnson & Johnson, Kaken Pharmaceutical Strike Licensing Agreement for the STAT6 Program That Targets Autoimmune, Allergic Diseases - Pharmaceutical Executive","headline":"Johnson & Johnson, Kaken Pharmaceutical Strike Licensing Agreement for the STAT6 Program That Targets Autoimmune, Allerg","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}